Human Intestinal Inflammation Assay.
InflammaScreen screens anti-inflammatory compounds on human colon tissue grown from RepliGut® Planar. It is a ready-to-run intestinal inflammation assay with three defined readouts and results in as little as three weeks.
Start a screenSee how it worksWhy anti-inflammatory screening needs human tissue
Inflammatory bowel disease affects an estimated 2.4 to 3.1 million Americans. Many patients still cycle through treatments that do not work or bring harmful side effects.
A major reason therapies stall is that legacy models cannot reproduce how the human intestinal epithelium responds to inflammation. That is why we built an intestinal inflammation assay on real human colon tissue. Because the biology is human from the start, your screen reflects the response that matters. Regulators are moving the same way, toward human-relevant New Approach Methodologies.
A fast, defined screen
One intestinal inflammation assay, three biological readouts
Each readout answers a different question. Together, they show whether a compound protects the epithelium or drives more damage.
Measure barrier function with TEER
Trans-epithelial electrical resistance is tracked across the timecourse to show how well the barrier holds under inflammatory stress.
Quantify cell damage with LDH
LDH release at 48 hours reveals whether a compound protects the epithelium or harms it.
Track signaling with IL-8
IL-8 at 48 hours reports pathway-dependent inflammatory cytokine release from the tissue.
Pre-treat, challenge, then read out
Fully mature RepliGut® Planar Transverse Colon monolayers grow on a porous membrane, with an apical reservoir above and a basal reservoir below. First we pre-treat the tissue with your test compounds. Then we add the pro-inflammatory cytokine TNF-alpha to trigger epithelial damage.
TEER is tracked across the timecourse to follow barrier function. LDH and IL-8 are then measured at 48 hours. So a single run shows whether a compound blocks or augments the human epithelial inflammatory response.
From compounds to answers in five steps
Ship your compounds to Altis and confirm the plate design.
We pre-treat mature RepliGut® Planar with your compounds.
TNF-alpha challenge initiates the epithelial damage.
We track TEER across the run, then collect LDH and IL-8 at 48 hours.
You receive the full dataset in as little as three weeks.
Defined readouts, validated in our lab
The assay is validated before it runs. Below is representative InflammaScreen data across all three readouts.
Download the interactive platemap
See how your compounds map onto a plate
Explore the layout, adjust it, and design your screen before you ship. Test up to ten compounds per plate for prevention of inflammatory damage and signaling.
Model the disease, or add immune cells
InflammaScreen is one of several ways to run RepliGut® in your program. Explore the full Services menu and the RepliGut® platform family.
Inflammatory bowel disease models
See how RepliGut® supports IBD discovery beyond screening, from barrier biology to repair.
Explore IBD modelsRepliGut® Immune Co-Culture
Add human immune cells beneath the epithelium to study immune-driven inflammation directly.
Explore Immune Co-CultureReady to screen anti-inflammatory leads in human tissue?
Ship your compounds and get three defined readouts from our intestinal inflammation assay in as little as three weeks.
Start your screenGet in touch with us
Have a question?
Want to learn more about RepliGut® Systems? Send us a Message